TEK and bronchopulmonary dysplasia: Third, we experimentally validate the mechanistic angiogenic, inflammatory, cell death and cell proliferation pathways of miR-34a, focusing on the role of vascular downstream targets, Ang1 and Tie2, and show that Ang1 treatment is protective of the BPD pulmonary and associated PAH phenotypes.